drugset / Trial / NCT00158613

Study of the Treatment of Articular Repair (STAR)

NCT00158613 ↗

Phase 4 Completed 126 enrolled Vericel Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is a prospective, longitudinal, multi-center, within patient evaluation of patients with articular cartilage defects of the knee who have had an inadequate response to a prior non-Carticel surgical treatment. Patients who met eligibility criteria were enrolled in the study. Subsequent to implantation with Carticel patients have follow-up every 6-months up to 48-months.

Timeline

Start
2000-03
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MACI Cell therapy 1.2e+07 cells Other